Ser372
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser372  -  GJA1 (human)

Site Information
sRAssRAssRPRPDD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 465460

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 4 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 3 ) , mutation of modification site ( 1 , 4 ) , phospho-antibody ( 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
ovarian cancer ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , IAR20 (epithelial) ( 1 ) , ovary ( 3 ) , stromal ( 2 ) , trophoblast ( 1 )

Upstream Regulation
Kinases, in vitro:
PKCA (human) ( 4 )
Treatments:
cAMP_analog ( 1 )

Downstream Regulation
Effects of modification on GJA1:
protein conformation ( 4 )

References 

1

Dukic AR, et al. (2017) Ezrin-anchored PKA phosphorylates serine 369 and 373 on connexin 43 to enhance gap junction assembly, communication, and cell fusion. Biochem J
29259079   Curated Info

2

Balla P, et al. (2015) Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone. PLoS One 10, e0125316
25933380   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

4

Grosely R, et al. (2013) Effects of Phosphorylation on the Structure and Backbone Dynamics of the Intrinsically Disordered Connexin43 C-terminal Domain. J Biol Chem 288, 24857-70
23828237   Curated Info